

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER <div style="text-align: center; font-size: 1.2em;">065691-0424</div> <div style="text-align: center; font-size: 1.5em; font-weight: bold;">304560449</div> <div style="text-align: center; font-size: 0.8em;">U.S. APPLICATION NO. (known as Sec. 37 C.F.R. 1.5) Unassigned</div>
INTERNATIONAL APPLICATION NO. PCT/FR2004/001462	INTERNATIONAL FILING DATE 06/11/2004	PRIORITY DATE CLAIMED 06/13/2003
TITLE OF INVENTION USE OF ALVERINE, ALONE OR IN COMBINATION WITH A TRICYCLIC ANTIDEPRESSANT OR AN ANTIDEPRESSANT WHICH IS A SPECIFIC INHIBITOR OF SEROTONIN REUPTAKE FOR TREATMENT OF DEPRESSION		
APPLICANT(S) FOR DO/EO/US Jacques MIGEON et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <div style="margin-left: 20px;"> <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) </div> 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <div style="margin-left: 20px;"> <input checked="" type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). </div> 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <div style="margin-left: 20px;"> <input type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. </div> 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 to 20 below concern other document(s) or information included:		
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A Preliminary Amendment. 14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Copy of International Search Report (2 pages). 		

IAP20 Rec'd PCT/PTO 13 DEC 2005

US APPLICATION NO. (If known, see 37 CFR. 1.53) 10/7560449 Unassigned		INTERNATIONAL APPLICATION NO. PCT/FR2004/001462		ATTORNEY'S DOCKET NUMBER 065691-0424	
--	--	--	--	---	--

The following fees have been submitted:					
21. <input checked="" type="checkbox"/>	Basic national fee	\$300		\$ 300.00	
22. <input checked="" type="checkbox"/>	Examination fee				
If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$100					
All other situations \$200					
23. <input checked="" type="checkbox"/>	Search fee				
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$100					
International Search Report prepared and provided to the Office \$400					
All other situations \$500					
TOTAL OF ABOVE 21, 22 and 23 =				\$ 1000.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
39 - 100 = 0	/50 =	3	x \$250.00	\$ 0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e))				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20 - 20 = 0		x \$ 50.00	\$ 0.00	
Independent Claims	1 - 3 = 0		x \$ 200.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 360.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 1130.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.				\$ 0.00	
SUBTOTAL =				\$ 1130.00	
Processing fee of 130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 1130.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). 40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 1130.00	
				Amount to be refunded:	
				charged:	

a. ☒ A check in the amount of \$1130.00 to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 19-0741 in the amount of \$1130.00 to cover the above fees. A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0741. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charge to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Foley & Lardner LLP
Customer Number: 22428


 SIGNATURE
 Stephen B. Maebius
 NAME
 35,264
 REGISTRATION NUMBER

**IN THE MATTER OF the Entry into
National Phase in USA
PCT/FR2004/001462
dated June 11, 2004**

**I, Magali TOUROUDE, C/O CABINET REGIMBEAU, of 20 rue de Chazelles,
F-75847 PARIS CEDEX 17, France, do solemnly and sincerely declare that I am
conversant with the English and French languages and am a competent
translator thereof, and that to the best of my knowledge and belief the following
is a true and correct translation of the International Publication of
PCT/FR2004/001462 dated of June 11, 2004.**

**For : USE OF ALVERINE, ALONE OR IN COMBINATION WITH A
TRICYCLIC ANTIDEPRESSANT OR AN ANTIDEPRESSANT WHICH IS A
SPECIFIC INHIBITOR OF SEROTONIN REUPTAKE FOR TREATMENT
OF DEPRESSION**

Date : December 9, 2005

A handwritten signature in black ink, appearing to read 'Touroude', with a large loop at the beginning and a horizontal line extending to the right.

**Magali TOUROUDE
For and on behalf of
CABINET REGIMBEAU**